SBIR Phase I: Optical Coherence Tomography(OCT)-Sensor Guided Sub-Retinal Injector

SBIR 第一阶段：光学相干断层扫描 (OCT) - 传感器引导视网膜下注射器

• 批准号: 1819719
• 负责人: Lok Chu
• 金额: $ 22.5万
• 依托单位: LIV Medical Technology Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-01 至 2020-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1819719&HistoricalAwards=false
• 关键词: SBIR; Phase; Optical; Coherence; Tomography

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is to address the most common causes of blindness worldwide. Retinal diseases account for vision loss in over 25 million Americans. Worldwide, the prevalence of blindness in children is determined largely by socioeconomic development and availability preventative care. By 2020, the World Health Organization estimates that visual impairment among children age 14 and under will reach almost 19 million, and adults will reach almost 266 million. This SBIR Phase I project proposes a SMART surgical tool to enable safe and precise delivery of stem cells and genes to help repair and restore the vision of patients with retinal degeneration. Studies have shown cell transplant technology and injectable therapeutics improve vision in afflicted patients. However, due to the delicate nature of retinal tissue, this procedure is challenging to perform successfully. The proposed tool addresses the unmet need for better visualization and targeted delivery of therapeutic agents. Precise delivery of treatment is expected to deliver benefits in preventing and correcting retinal diseases.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业创新研究（SBIR）项目的更广泛的影响/商业潜力是解决世界上最常见的失明原因。超过2500万美国人因视网膜疾病丧失视力。在世界范围内，儿童失明的流行程度主要取决于社会经济发展和预防保健的可得性。世界卫生组织估计，到2020年，14岁及以下儿童中视力受损的人数将达到近1900万，成年人将达到近2.66亿。这个SBIR一期项目提出了一种SMART手术工具，可以安全精确地输送干细胞和基因，帮助修复和恢复视网膜变性患者的视力。研究表明，细胞移植技术和注射疗法可以改善患者的视力。然而，由于视网膜组织的脆弱性质，这一过程是具有挑战性的成功执行。提出的工具解决了对更好的可视化和靶向递送治疗剂的未满足需求。精准的治疗有望在预防和纠正视网膜疾病方面带来益处。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。